A coating composition and related method for use in applying a bioactive agent to a surface in a manner that will permit the bioactive agent to be released from the coating in vivo. The composition is particularly well suited for coating the surface of implantable medical device, such as a stent or
A coating composition and related method for use in applying a bioactive agent to a surface in a manner that will permit the bioactive agent to be released from the coating in vivo. The composition is particularly well suited for coating the surface of implantable medical device, such as a stent or catheter, in order to permit the device to release bioactive agent to the surrounding tissue over time. The composition includes a plurality of compatible polymers having different properties that can permit them to be combined together to provide an optimal combination of such properties as durability, biocompatibility, and release kinetics.
대표청구항▼
What is claimed is: 1. A composition for coating the surface of a medical device with at least one bioactive agent in a manner that permits the coated surface to release the bioactive agent over time when implanted in vivo, the composition comprising at least one bioactive agent in combination with
What is claimed is: 1. A composition for coating the surface of a medical device with at least one bioactive agent in a manner that permits the coated surface to release the bioactive agent over time when implanted in vivo, the composition comprising at least one bioactive agent in combination with a plurality of polymers, including a first polymer component comprising at least one epichlorohydrin-containing polymer and a second polymer component comprising a polymer selected from the group consisting of poly(alkyl(meth)acrylates) and poly(aromatic(meth)acrylates). 2. A composition according to claim 1 wherein the first polymer component is a poly(epichlorohydrin-co-alkylene oxide). 3. A composition according to claim 2 wherein the poly(epichlorohydrin-co-alkylene oxide) is poly(epichlorohydrin-co-ethylene oxide). 4. A composition according to claim 1 wherein the first polymer component includes a homopolymer derived from epichlorohydrin. 5. A composition according to claim 1 wherein the epichlorohydrin-containing polymer includes an epichlorohydrin content of from about 30% to 100%. 6. A composition according to claim 5 wherein the epichlorophydrin-containing polymer includes an epichlorohydrin content of from about 50% to 100%. 7. A composition according to claim 1 wherein the epichlorohydrin-containing polymers have a weight average molecular weight from about 100 kilodaltons to about 300 kilodaltons. 8. A composition according to claim 1, the first polymer component having a molecular weight from about 100 kilodaltons to about 300 kilodaltons. 9. A composition according to claim 1 wherein the composition includes at least one additional polymer selected from the group consisting of poly(alkylene-co-alkyl(meth)acrylates), ethylene copolymers with other alkylenes, polybutenes, diolefin derived non-aromatic polymers and copolymers, aromatic group-containing copolymers, and poly (ethylene-co-vinyl acetate). 10. A composition according to claim 9 wherein the poly(alkylene-co-alkyl(meth)acrylates) are selected from the group consisting of poly(ethylene-co-methyl acrylate), poly(ethylene-co-ethyl acrylate), poly(ethylene-co-2-ethylhexyl acrylate) and poly(ethylene-co-butyl acrylate), ethylene copolymers with other alkylenes are selected from the group consisting of poly(ethylene-co-propylene), poly(ethylene-co-1-butene), poly(ethylene-co-1-butene-co-1-hexene) and poly(ethylene-co-1-octene), the polybutenes are selected from the group consisting of polyisobutylene, poly-1-butene and poly-2-butene, the diolefin derived non-aromatic polymers and copolymers are selected from the group consisting of polybutadiene, poly(butadiene-co-acrylonitrile), polybutadiene-block-polyisoprene, polybutadiene-graft-poly(methyl acrylate-co-acrylonitrile), polyisoprene and partially hydrogenated polyisoprene, the aromatic group-containing copolymers include a copolymer derived from copolymerization of styrene monomer and one or more monomers selected from the group consisting of butadiene, isoprene, acrylonitrile, a C1-C4 alkyl (meth)acrylate and butene, and the poly (ethylene-co-vinyl acetate) polymers have a vinyl acetate concentration from about 8% to about 90%. 11. A composition according to claim 1 wherein the poly(alkyl(meth)acrylate) includes an alkyl chain length from two to eight carbons. 12. A composition according to claim 1, wherein the poly(alkyl(meth)acrylate) has a molecular weight from about 50 kilodaltons to about 900 kilodaltons. 13. A composition according to claim 1 wherein the poly(alkyl(meth)acrylate) is selected from the group consisting of poly(n-butyl methacrylate), poly(n-butyl methacrylate-co-isobutyl methacrylate), and poly(t-butyl methacrylate). 14. A composition according to claim 1 wherein the poly(aromatic(meth)acrylate) includes aryl groups having from six to sixteen carbon atoms. 15. A composition according to claim 1, wherein the poly(aromatic(meth)acrylate) has a molecular weight from about 50 kilodaltons to about 900 kilodaltons. 16. A composition according to claim 1 wherein the poly(aromatic(meth)acrylate) is selected from the group consisting of poly(aryl (meth)acrylates), poly(aralkyl (meth)acrylates), poly(alkaryl (meth)acrylates), poly(aryloxyalkyl (meth)acrylates), and poly (alkoxyaryl (meth)acrylates). 17. A composition according to claim 16, wherein the poly(aryl (meth)acrylates) are selected from the group consisting of poly(9-anthracenyl methacrylate), poly(chlorophenyl acrylate), poly(methacryloxy-2-hydroxybenzophenone), poly(methacryloxybenzotriazole), poly(naphthyl acrylate), poly(naphthylmethacrylate), poly-4-nitrophenylacrylate, poly(pentachloro(bromo, fluoro) acrylate) and methacrylate, poly(phenyl acrylate) and poly(phenyl methacrylate); the poly(aralkyl (meth)acrylates) are selected from the group consisting of poly(benzyl acrylate), poly(benzyl methacrylate), poly(2-phenethyl acrylate), poly(2-phenethyl methacrylate) and poly(1-pyrenylmethyl methacrylate); the poly(alkaryl(meth)acrylates) are selected from the group consisting of poly(4-sec-butylphenyl methacrylate), poly(3-ethylphenyl acrylate), and poly(2-methyl-1-naphthyl methacrylate); the poly(aryloxyalkyl (meth)acrylates) are selected from the group consisting of poly(phenoxyethyl acrylate), poly(phenoxyethyl methacrylate), and poly(polyethylene glycol phenyl ether acrylate) and poly(polyethylene glycol phenyl ether methacrylate) with varying polyethylene glycol molecular weights; and the poly(alkoxyaryl(meth)acrylates) are selected from the group consisting of poly(4-methoxyphenyl methacrylate), poly(2-ethoxyphenyl acrylate) and poly(2-methoxynaphthyl acrylate). 18. A composition according to claim 1 wherein the composition further comprises a solvent in which the first and second polymer components form a true solution. 19. A composition according to claim 1 wherein the composition includes a bioactive agent at a concentration of 0.01% to 90% by weight. 20. A composition according to claim 1 wherein the device is one that undergoes flexion and expansion in the course of implantation or use in vivo. 21. A composition according to claim 1 wherein the composition permits the amount and rate of release of bioactive agent(s) from the medical device to be controlled by adjusting the relative types and concentrations of the first and second polymer components in the mixture. 22. A combination comprising a medical device and a composition for coating the surface of the medical device with at least one bioactive agent in a manner that permits the coated surface to release the bioactive agent over time when implanted in vivo, the composition comprising at least one bioactive agent in combination with a plurality of polymers, including a first polymer component comprising at least one epichlorohydrin-containing polymer and a second polymer component comprising a polymer selected from the group consisting of poly(alkyl(meth)acrylates) and poly(aromatic(meth)acrylates). 23. The combination of claim 22 wherein a pretreatment coating, adapted to alter the surface properties of the medical device, is applied to the surface of the medical device. 24. The combination according to claim 22 wherein the first polymer component is a poly(epichlorohydrin-co-alkylene oxide). 25. The combination according to claim 22 wherein the first polymer component includes a homopolymer derived from epichlorohydrin. 26. The combination according to claim 22 wherein the epichlorohydrin-containing polymer includes an epichlorohydrin content of from about 30% to 100%. 27. The combination according to claim 22 wherein the epichlorohydrin-containing polymers have a weight average molecular weight from about 100 kilodaltons to about 300 kilodaltons. 28. The combination according to claim 22 wherein the composition includes at least one additional polymer selected from the group consisting of poly(alkylene-co-alkyl(meth)acrylates), ethylene copolymers with other alkylenes, polybutenes, diolefin derived non-aromatic polymers and copolymers, aromatic group-containing copolymers, and poly (ethylene-co-vinyl acetate). 29. The combination according to claim 23 wherein the pretreatment coating includes one or more materials selected from the group consisting of Parylene®, silane, photografted polymers, epoxy primers, polycarboxylate resins and combinations thereof. 30. The combination according to claim 22 wherein the composition permits the amount and rate of release of agent(s) from the medical device to be controlled by adjusting the relative types and concentrations of the first and second polymer components in the mixture. 31. A composition for coating the surface of a medical device with at least one bioactive agent in a manner that permits the coated surface to release the bioactive agent over time when implanted in vivo, the composition comprising at least one bioactive agent in combination with a plurality of polymers, including a first polymer component comprising at least one epichlorohydrin-containing polymer and a second polymer component comprising a polymer selected from the group consisting of poly(alkyl(meth)acrylates) and poly(aromatic(meth)acrylates), wherein the composition includes at least one additional polymer selected from the group consisting of poly(alkylene-co-alkyl(meth)acrylates), ethylene copolymers with other alkylenes, polybutenes, diolefin derived non-aromatic polymers and copolymers, aromatic group-containing copolymers, and poly (ethylene-co-vinyl acetate). 32. A method of delivering at least one bioactive agent from a surface of a medical device to an animal comprising providing a composition including at least one bioactive agent in combination with a plurality of polymers, including a first polymer component comprising at least one epichlorohydrin-containing polymer and a second polymer component comprising a polymer selected from the group consisting of poly(alkyl(meth)acrylates) and poly(aromatic(meth)acrylates), applying the composition to the surface of the device and administering the medical device to the animal. 33. A combination comprising a stent and a composition for coating the surface of a stent with at least one bioactive agent in a manner that permits the coated surface to release the bioactive agent over time when implanted in vivo, the composition comprising at least one bioactive agent in combination with a plurality of polymers, including a first polymer component comprising a poly(epichlorohydrin), a second polymer component comprising poly(n-butyl methacrylate), a solvent in which the first and second polymer components form a true solution, and at least one biocompatible additive, and further comprising a pretreatment layer including a multi-interface system to facilitate adhesion and cohesion interaction relative to the stent and coating composition. 34. A combination according to claim 33, wherein the bioactive agent is selected from the group consisting of rapamycin, paclitaxel, dexamethasone, and estradiol. 35. A combination according to claim 33, wherein the stent includes a material selected from the group consisting of polymers, tissue, metals, ceramics, and combinations thereof. 36. A combination according to claim 35, wherein the polymers include polycarbonates and the metals are selected from the group consisting of titanium, stainless steel, gold, silver, and nitinol. 37. A combination according to claim 33, wherein the solvent is selected from the group consisting of tetrahydrofuran, chloroform, methylene chloride, toluene, cyclohexane and combinations thereof. 38. A combination according to claim 33, wherein the biocompatible additive includes one or more antioxidants selected from the group consisting of butylated hydroxytoluene, vitamin E, BNX, and dilauryl thiodipropionate. 39. A combination according to claim 33, wherein the pretreatment layer includes organosilane and Parylene®. 40. A composition according to claim 1, further comprising a pretreatment layer including a multi-interface system to facilitate adhesion and cohesion interaction relative to the medical device and composition. 41. A composition according to claim 40, wherein the pretreatment layer includes organosilane and Parylene®. 42. A combination comprising a medical device and a composition for coating the surface of a medical device with at least one bioactive agent in a manner that permits the coated surface to release the bioactive agent over time when implanted in vivo, the composition comprising at least one bioactive agent in combination with a plurality of polymers, including a first polymer component comprising poly(epichlorohydrin), a second polymer component comprising poly(n-butyl methacrylate), a solvent in which the first and second polymer components form a true solution selected from the group consisting of tetrahydrofuran, chloroform, methylene chloride, and cyclohexane, and at least one biocompatible additive including one or more antioxidants selected from the group consisting of butylated hydroxytoluene, vitamin E, BNX, and dilauryl thiodipropionate, and further comprising a pretreatment layer including a multi-interface system to facilitate adhesion and cohesion interaction relative to the medical device and coating composition. 43. A combination according to claim 42, wherein the bioactive agent is selected from the group consisting of rapamycin, paclitaxel, dexamethasone, and estradiol. 44. The combination of claim 42 further comprising a topcoat including poly(butyl methacrylate). 45. The combination of claim 42, wherein the medical device comprises a stent.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (182)
Bezwada Rao S. (Whitehouse Station NJ) Arnold Steven C. (Sparta NJ) Ace Constance (Whitehouse NJ), Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer.
Domb Abraham J. (Baltimore MD) Shikani Alain (Baltimore MD) Haffer Andrew S. T. (Baltimore MD) Maniar Manoj (Baltimore MD), Anti-infective and anti-inflammatory releasing systems for medical devices.
Solomon Donald D. (Spring Valley OH) Byron M. Parke (Centerville OH), Anti-infective and antithrombogenic medical articles and method for their preparation.
Solomon Donald D. (Spring Valley OH) Byron M. Parke (Centerville OH), Anti-infective and antithrombogenic medical articles and method for their preparation.
Cahalan Linda L. (Geleen NLX) Cahalan Patrick T. (Geleen NLX) Verhoeven Michel (Maastricht NLX) Hendriks Marc (Hoensbroek NLX) Fouache Benedicte (Maastricht NLX), Biocompatible medical article and method.
Bezwada Rao S. (Whitehouse Station NJ) Jamiolkowski Dennis D. (Long Valley NJ), Blends of absorbable polyoxaesters containing amines and/or amido groups.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Hossainy, Syed F. A.; Pacetti, Stephen D.; Fong, Keith E.; Bhat, Vinayak; Sanders Millare, Deborra; Guruwaiya, Judy A.; Mirzaee, Daryush; Mandrusov, Evgenia, Coating for implantable devices and a method of forming the same.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Helmus, Michael N.; Cunanan, Crystal M.; Tremble, Patrice, Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic intimal hyperplasia.
Shah Kishore (Bridgewater NJ) Kydonieus Agis (Kendall Park NJ), Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate c.
Eury Robert P. (Cupertino CA) Garguilo Darlene (Fremont CA) Villareal Plaridel (San Jose CA), Drug loaded polymeric material and method of manufacture.
Sabel Bernhard A. (Kreuzberg 6 8011 Egmating MA DEX) Freese Andrew (115 Whitcomb Ave. Jamaica Plain MA 02130), Extended drug delivery of small, water-soluble molecules.
Bezwada Rao S. (Whitehouse Station NJ) Cooper Kevin (Warren NJ) Jamiolkowski Dennis D. (Long Valley NJ) Newman ; Jr. Hugh D. (Chester NJ), High strength, fast absorbing, melt processable, gycolide-rich, poly(glycolide-co-p-dioxanone) copolymers.
Bezwada Rao S. (Whitehouse Station NJ) Cooper Kevin (Warren NJ), High strength, melt processable, lactide-rich, poly(lactide-CO-P-dioxanone) copolymers.
Fox ; Jr. Charles L. (New York NY) Modak Shanta M. (River Edge NJ) Sampath Lester A. (Nyack NY), Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same.
Fischell Robert E. (Silver Spring MD) Fischell Tim A. (Palo Alto CA), Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the preventi.
Fan You Ling ; Marlin Lawrence ; Bouldin Lisa M. ; Marino Isabel Maria, Lubricious coatings containing polymers with vinyl and carboxylic acid moieties.
Tang Reginald T. (Warren NJ) Mares Frank (Whippany NJ) Boyle ; Jr. William J. (Parsippany NJ) Chiu Tin-Ho (Millburn NJ) Patel Kundanbhai M. (Landing NJ), Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lact.
Shikani Alain H. (Ruxton MD) Domb Abraham J. (Efrat ILX), Method and device for inhibiting H.I.V. hepatitis B and other viruses and germs when using a needle, scalpel and other s.
Sasisekharan Ramnath (Arlington MA) Moses Marsha A. (Brookline MA) Nugent Matthew A. (Bedford MA) Cooney Charles L. (Brookline MA) Langer Robert S. (Newton MA), Method for inhibiting angiogenesis using heparinase.
Nesburn Anthony B. (Malibu CA) Gorin Michael (Rockville MD) Martinez Marvin (Glendale CA) Kenney M. Cristina (Malibu CA) Maguen Ezra (Los Angeles CA), Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers.
Nesburn Anthony B. (Malibu CA) Gorin Michael B. (Pittsburgh PA) Kenney M. Cristina (Malibu CA) Maguen Ezra (Los Angeles CA), Method of crosslinking amino acid-containing polymers using photoactivatable chemical crosslinkers.
Good A. Heather (Edmonton CAX) Cooper David K. C. (Oklahoma City OK) Malcolm Andrew J. (Edmonton CAX), Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients.
Robinson, Michael R.; Csaky, Karl G.; Yuan, Peng; Sung, Cynthia; Nussenblatt, Robert B.; Smith, Janine A., Ocular therapeutic agent delivery devices and methods for making and using such devices.
Swanson Melvin J. ; Amos Richard A. ; Swan Dale G. ; Opperman Gary W., Photoactivatable chain transfer agents and semi-telechelic photoactivatable polymers prepared therefrom.
Clapper David L. ; Swanson Melvin J. ; Hu Sheau-Ping ; Amos Richard A. ; Everson Terrence P., Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups.
Tartaglia Joseph M. (Redwood City CA) Loeffler Joseph P. (Mountain View CA) Turnlund Todd H. (Mountain View CA), Polymer film for wrapping a stent structure.
Dean Laurin ; Angeles Lillian Buan ; Lecon Woo ; Michael T. K. Ling ; Yuan Pang Samuel Ding ; William Anderson ; Larry A. Rosenbaum ; Denise S. Hayward ; Joseph P. Hoppesch ; Gregg Nebgen ;, Polymeric compositions for medical packaging and devices.
Swan Dale G. (St. Louis Park MN) Josephson Mark W. (Richfield MN) Swanson Melvin J. (Carver MN), Preparation of crosslinked matrices containing covalently immobilized chemical species and unbound releasable chemical s.
Mathiowitz Edith ; Jacob Jules S. ; Chickering ; III Donald E. ; Pekarek Kathleen Jo, Preparation of multiwall polymeric microcapsules from hydrophilic polymers.
Mathiowitz, Edith; Jacob, Jules S.; Chickering, III, Donald E.; Pekarek, Kathleen Jo, Preparation of multiwall polymeric microcapsules from hydrophilic polymers.
Guire Patrick E. (Eden Prairie MN) Dunkirk Shawn G. (Eden Prairie MN) Josephson Mark W. (Richfield MN) Swanson Melvin J. (Carver MN), Preparation of polymeric surfaces via covalently attaching polymers.
Duran Lise W. ; Swanson Melvin J. ; Amos Richard A. ; Hu Sheau-Ping J. ; Guire Patrick E., Reagent and method for attaching target molecules to a surface.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Miranda Jesus (Miami FL) Sablotsky Steven (Miami FL), Solubility parameter based drug delivery system and method for altering drug saturation concentration.
Oshlack Benjamin ; Chasin Mark ; Pedi ; Jr. Frank, Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer.
Guire Patrick E. (Eden Prairie MN) Dunkirk Shawn G. (Eden Prairie MN) Josephson Mark W. (Richfield MN) Swanson Melvin J. (Carver MN), Substrate surface preparation.
Aoki ; Y. ; et al. ; "Effects of Recombinant Human Soluble Thrombomodulin (rhs-TM) on a Rat Model of Disseminated Intravascular Coagulation with Decreased Levels of Plasma Antithrombin" Thrombosis an, Surface modifying composition and method.
Noelle Christine Vook ; Elliott Jacob ; Jean A. Setterstrom ; John van Hamont ; William Vaughan ; Ha Duong, Sustained release hydrophobic bioactive PLGA microspheres.
Weiner Alan L. (Cranbury NJ) Sinnett Kevin (Mukwonago WI) Johnson Sterling (Skillman NJ), Tack for intraocular drug delivery and method for inserting and removing same.
Setterstrom Jean A. ; Van Hamont John E. ; Reid Robert H. ; Jacob Elliot ; Jeyanthi Ramasubbu ; Boedeker Edgar C. ; McQueen Charles E. ; Jarboe Daniel L. ; Cassels Frederick ; Brown William ; Thies C, Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix.
Fearnot Neal E. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees ; III William D. (West Lafayette IN), Thrombolytic treated intravascular medical device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.